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Pyrazolylaminoquinazoline is obtained from synthetic AZD4547 and can inhibit kinase activity in recombinant 
fibroblast growth factor receptor (FGFR) in vitro. The objective of this study was to obtain high activity and low 
toxicity pyrazolylaminoquinazoline derivatives in silico. The 2-dimensional structures were generated using the 
ChemDraw application. The Lazar application was used to predict endpoint carcinogenicity, maximum daily dose, 
and mutagenicity. The ProTox application was used for endpoint LD50 and toxicity classes, while the ADMET 
application was used for endpoint hepatotoxicity, with reproductive system disorders, and endocrine. Based on the 
scoring from the three software applications, two compounds were identified as being active against FGFR 2, with no 
carcinogenic or toxic effects on the liver, endocrine system, and the reproductive system, but they were predicted to 
have mutagenic effects. These compounds were V29 (N-(5-(3,5-dimethoxy phenethyl -1H-pyrazol-3-yl)-7(octahydro-
2H-pyrido[1,2-a]pyrazine-2-yl) quinazoline-4-amine), with an IC50 of 0.2 ± 0.1 nM and a toxicity score of 1027, and 
V32 (N-(5-(3,5-dimethoxy phenethyl)-1H-pyrazol-3-yl)-7-(4-(dimethylamino)piperidine-1-yl)quinazoline-4-amine), 
with an IC50 of 0.3 ± 0.1 nM and a toxicity score of 1024.
Key words: 
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Pirazolilaminokuinazoline, 
Lazar, ProTox, ADMET 
PredictorTM.
INTRODUCTION
Many bioactive compounds have been shown to have 
anticancer activity, but their uses are limited due to side effects and 
high toxic effects (Malchers et al., 2017). Nonetheless, toxicity 
can be assessed using computational resources (computational 
algorithms, software, and data) to organize, analyze, model, 
simulate, visualize, or predict chemical toxicity (Raies and Bajic, 
2016). Predicted toxicity in silico is performed prior to in vitro 
and in vivo testing to minimize the number of test compounds and 
test animals in subsequent tests. Such in silico tests include Lazy 
Structure-Activity Relationships (Lazar), Prediction of Rodent 
Oral Toxicity (ProTox), and ADMET PredictorTM.
Lazar is a useful tool to predict the toxic properties of 
chemical structures. It produces predictions for the query structure 
of the database with experimentally determined toxicity data in the 
quantitative QSAR (quantitative structure-activity relationship) 
statistical approach. The performance of the Lazar software model 
in the external validation dataset has an accuracy of 86% and a 
sensitivity of 78% in the carcinogenicity test, with 95% accuracy 
for the mutagenicity test (Helma, 2006).
ProTox is a web server for predicting small molecule 
oral toxicity in rodents. LD50 and toxicity classes are calculated 
on the basis of chemical compounds similar to those of toxic 
compounds. Researchers rely on known toxicity data to develop 
models that can predict the toxicity of new compounds. This 
web server calculates sensitivity, specificity, and precision for all 
considered toxicity classes, with values of 76%, 95%, and 75% 
(Drwal et al., 2014).
ADMET PredictorTM uses integrated sequences to 
examine how the molecular structure of a compound plays a role 
in absorption, distribution, metabolism, excretion, and toxicology. 
The classification accuracy qualitatively reaches 85–90%. The 
program has an intuitive user interface that allows visualization of 
the data (Hassan et al., 2013).
Pyrazolylaminoquinazoline derivative compounds 
can inhibit the fibroblast growth factor receptor (FGFR). 
Indeed, pyrazolilaminoquinazoline derivatives synthesized 
from AZD4547 have been shown to be effective, via targeting 
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FGFR, against leukaemia in the KG-1 cell line (Gu et al., 2006), 
gastric cancer in the KATO III cell line (Kunii et al., 2008), 
bladder cancer in the RT112 cell line (Wang et al., 2014), and 
lung cancer in the H1581 cell line (Malchers et al., 2017). The 
IC50 values ranged from 0.2–10 Nm, but their toxicity was not 
determined. Therefore, this study aimed to predict the toxicity 
of pyrazolylaminoquinazoline derivatives in silico using Lazar, 
ProTox and ADMET PredictorTM applications. The results will 
help in the selection of anticancer drugs with high activity, but low 
toxicity prior to in vivo toxicity through preclinical testing. This is 
particularly important as in vivo animal testing is limited by time, 
ethical considerations, and a financial burden.
MATERIALS AND METHODS
Equipment and materials
The hardware used in this study was a PC with AMD 
A8-7410 Quad Core 2.2-2.5 GHz specification, with 4 gigabytes 
of DDR3 RAM and a Windows 10 Pro 64-bit operating system. 
The software used were ChemDraw Pro 16.0 (http://scistore.
cambridgesoft.com/) under license code: 338-428260-4806, 
pkCSM (http://biosig.unimelb.edu.au/pkcsm/), Open Babel GUI 
(http://openbabel.org/wiki/Category:Installation), Lazar (https://
lazar.in-silico.ch/predict), ProTox (http://tox.charite.de/tox/), and 
ADMET PredictorTM v8.0.4.62016 (http://simplusdownloads.com/ 
LicensingInstructions/AP8.html) with activation ID: 537-778-03-
08-2017-10-03-11-5095, Node Locked ID: CF9B5E81DD7C, 
and License Model: FIXED. The pyrazolylaminoquinazoline 
derivatives analyzed with IC50 values according to Fan et al., 
(2016) are shown in Table 1.
Experimental procedure
The 2D structure of 37 pyrazolylaminoquinazoline 
compounds was generated using the ChemDraw 2016 application. 
All pyrazolylaminoquinazoline compounds were screened using 
the pkCSM application to determine whether the compounds 
met Lipinski’s Rule of Five. Compounds which did not meet 
the maximum two endpoints of Lipinski’s Rule of Five were 
eliminated. The toxicity of the screened pyrazolylaminoquinozoline 
compounds was then predicted using Lazar for the carcinogenic 
endpoint, maximum daily dose, and mutagenicity, the ProTox 
application for LD50 endpoint and toxicity classes, as well as the 
ADMET Predictor application for hepatotoxicity endpoint, as well 
as reproductive system disorders, and endocrine.
Table 1: Pyrazolylaminoquinazoline derivatives.
No. Comp. Code Structure IC50 (nM) Compound name
1 V2 <10
N4-(5-(3,5-dimethoxy phenethyl)-
1H-pyrazol-3-yl)-7-(4-ethylpipera-
zine-1-yl)-N2-((3-methylisoxazol-5-
yl) methyl)quinazoline-2,4-diamine
2 V3 0.8 ± 0.2
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(4-ethylpipera-
zine-1-yl) quinazoline-4-amine
3 V12 0.3 ± 0.1
N-(5-(2,6-dichloro-3,5-dimeth 
oxyphenethyl)-1H-pyrazol-3-yl)-7-
(4-ethylpiperazine-1-yl) quinazoline-
4-amine
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4 V13 29.9 ± 0.2
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(4-ethylpipera-
zine-1-yl) quinoline-4-amine
5 V14 0.6 ± 0.2
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(4-ethylpiper-
azine-1-yl)-2-methylquinazoline-4-
amine
6 V15 0.5 ± 0.1
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-2-ethyl-7-(4-
ethylpiperazine-1-yl) quinazoline-
4-amine
7 V16 0.7 ± 0.2
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(4-ethyl piper-
azine-1-yl)-2-propyl quinazoline-
4-amine
8 V17 3.2 ± 0.5 N-(5-(3,5-dimethoxy phenethyl)-1H-
pyrazol-3-yl) quinazoline-4-amine
9 V18 16.9 ± 0.2
5-chloro-N-(5-(3,5-dimethoxy 
phenethyl)-1H-pyrazol-3-yl) quinazo-
line-4-amine
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10 V19 100.9 ± 0.2
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-5-methoxy-
quinazoline-4-amine
11 V20 4.8 ± 0.9
8-chloro-N-(5-(3,5-dimethoxy 
phenethyl)-1H-pyrazol-3-yl) quinazo-
line-4-amine
12 V21 3.9 ± 0.1
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-8-methoxy-
quinazoline-4-amine
13 V22 4.3 ± 0.1
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-8-(4-ethylpipera-
zine-1-yl) quinazoline-4-amine
14 V23 1.0 ± 0.2
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(4-methylpipera-
zine-1-yl)quinazoline-4-amine
15 V24 0.6 ± 0.0
N-(5-(3,5-dimethoxy phenethyl)-1H-
pyrazol-3-yl)-7-(4-iso propylpipera-
zine-1-yl) quinazoline-4-amine
Supandi et al. / Journal of Applied Pharmaceutical Science 8 (09); 2018: 119-129 123
16 V25 0.6 ± 0.1
7-(4-cyclobutylpiperaz-
in-1-yl)-N-(5-(3,5-dimethoxy 
phenethyl)-1H-pyrazol-3-yl) quinazo-
line-4-amine
17 V26 0.7 ± 0.2
N-(5-(3,5-dimethoxy phenethyl)-1H-
pyrazol-3-yl)-7-(4-(2-methoxyethyl) 
piperazine-1-yl)-2-quinazoline-4-
amine
18 V27 4.18 ± 0.1
N-(5-(3,5-dimethoxy phenethyl)-1H-
pyrazol-3-yl)-7-(4-tosylpiperazine-1-
yl) quinazoline-4-amine
19 V28 0.9 ± 0.1
N-(5-(3,5-dimethoxy pheneth-
yl) -1H-pyrazol-3-yl)-7-(3,3-di 
methylpiperazine-1-yl) quinazoline-
4-amine
20 V29 0.2 ± 0.1
N-(5-(3,5-dimethoxy pheneth-
yl)-1H-pyrazol-3-yl)-7(octahy-
dro-2H-pyrido[1,2-a]pyrazine-2-yl)
quinazoline-4-amine
21 V30 0.2 ± 0.1
N-(5-(3,5-dimethoxy phenethyl)-
1H-pyrazol-3-yl)-7-((3S,5R)-3,4,5-
trimethyl piperazine-1-yl) quinazo-
line-4-amine
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22 V31 0.7 ± 0.2
N-(5-(3,5-dimethoxy phenethyl)-1H-
pyrazol-3-yl)-7-(4-methyl-1,4-diaze-
pan-1-yl)quinazoline-4-amine
23 V32 0.3 ± 0.1
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(4-(dimethyl-
amino) piperidin -1-yl) quinazoline-
4-amine
24 V33 0.4 ± 0.2
N-(5-(3,5-dimethoxy pheneth-
yl)-1H-pyrazol-3-yl)-7-(3-(dimethyl-
amino) pyrrolidin-1-yl)quinazoline-
4-amine
25 V34 0.8 ± 0.1
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(1-methylpiperi-
din-4-yl) quinazoline-4-amine
26 V35 0.87 ± 0.1
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(piperidin-1-yl)
quinazoline-4-amine
27 V36 0.4 ± 0.1
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-morpholino-
quinazoline-4-amine
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28 V37 1.3 ± 0.3
N4-(5-(3,5-dimethoxy pheneth-
yl)-1H-pyrazol-3-yl)-N7-(2-morphol-
inoethyl) quinazoline-4,7-diamine
29 V38 2.7 ± 0.2
N4-(5-(3,5-dimethoxy phenethyl)-
1H-pyrazol-3-yl)-N7-(2-methoxyeth-
yl) quinazoline-4,7-diamine
30 V39 0.9 ± 0.2
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-(2-methoxye-
thoxy) quinazoline-4-amine
31 V40 0.73
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-7-methoxy-
quinazoline-4-amine
32 V41 43.9
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-6-(2-methoxye-
thoxy) quinazoline-4-amine
33 V42 29.9
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-6-(4-ethylpiperaz-
in-1-yl) quinazoline-4-amine
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34 V43 58.8
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-6-methoxy-7-(2-
methoxy ethoxy)quinazoline-4-amine
35 V44 66.7
N-(5-(3,5-dimethoxy phenethyl)-1H-
pyrazol-3-yl)-7-(4-ethylpiperazin-1-
yl)-6-methoxy quinazoline-4-amine
36 V46 0.6 ± 0.2
2-chloro-N-(5-(3,5-dimethoxy 
phenethyl)-1H-pyrazol-3-yl)-7-(4-
ethylpiperazine-1-yl) quinazoline-
4-amine
37 V50
 
1.2 ± 0.2
N-(5-(3,5-dimethoxy phenethyl) 
-1H-pyrazol-3-yl)-6-(4-ethylpipera-
zine-1-yl) isoquinazoline-4-amine
Data analysis
The predictions were in the form of quantitative and 
qualitative data. Qualitative data were expressed in positive and 
negative statements, then expressed in the form of scoring, where 
a positive toxic score is 1 and a negative toxic score is 2. The 
data were scaled by summing all endpoints of the Lazar, ProTox, 
and ADMET predictions to obtain five compounds with the lowest 
toxicity, that is, the largest score. Five pyrazolylaminoquinazolin 
compounds were then selected which possessed high activity based 
on the in vitro test of Fan et al. (2016). The best compound was 
then obtained through the selected scoring model by comparing 
each compound with a low toxic effect, followed by the highest 
number of toxic negative endpoints. The next step selected two 
compounds with the highest activity and the lowest toxicity, by 
comparing the highest scores and the smallest IC50 value among 
the five compounds.
RESULTS AND DISCUSSION
Lipinski’s Rule of Five
Lipinski’s Rule of Five helps to determine the level of 
absorption or permeability of lipid bilayers present in the human 
body, demonstrating the oral bioavailability of a compound. Good 
bioavailability will satisfy the Lipinski rule, where the maximum 
molecular weight of the compound is 500, the log P is not more 
than 5, the donor hydrogen bond is not more than 5, and the 
number of hydrogen bond acceptor is less than 10 (Lipinski et al., 
2001). The results of the Lipinski’s Rule of Five calculations using 
pkCSM are presented in Table 2.
According to Table 2, all pyrazolylaminoquinazoline 
compounds met the Lipinski rule, so it can be predicted that all 
compounds have good absorptivity for oral medication. Veber 
et al. (2002) concluded that the lower molecular weight, log P, 
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hydrogen bond donors, and hydrogen bond acceptor, the higher 
the bioavailability of a candidate drug.
Toxicity prediction
Based on the results of Lazar, carcinogenicity test 
prediction of Carcinogenic Potency Database (CPDB) with 
Leave One Out (LOO) cross-validation of the compounds V14, 
V15, V18, V21, V25-V26, V29, V31, V34, V39-V43, and V46 
is non-carcinogenic, but V40 has the highest non-carcinogenic 
probability, with probability values 0.0895 for hamster, 0.102 for 
house mouse and 0.108 for mouse. The higher the non-carcinogen 
probability value, the higher the non-carcinogenic nature of a 
compound (Helma, 2006). Ranked from the highest to the lowest 
non-carcinogen probability values, the compounds are V40, V46, 
V41, V21, V31, V39, V42, V29, V14, V15, V43, V26, V18, 
V34, and V25, while compounds V30, V32, V35, and V36 are 
carcinogens. Regarding the maximum daily dose prediction, the 
smaller the maximum dose, the more toxic the compound. The 
maximum daily dose could not be predicted for most compounds 
due to the lack of similar structures, except for compound 
V13, which was 7.57 mg/kg BW/day. According to the in vitro 
mutagenicity prediction (Ames test) from the Kazius/Bursi dataset 
using LOO cross-validation in the CPDB application domain, 35 
compounds were predicted to have a risk of a mutagen. However, 
compound V29 had the lowest mutagen probability with a value of 
0.0988. The lower the probability value of mutagen, the lower the 
mutagen property of a compound (Helma, 2006).
Table 2: Lipinski’s Rule of Five Analysis Results.
Comp.
code BM (<500) LogP (<5) Hydrogen Bond Acceptor Hydrogen Bond Donor
Comp.
BM (<500) LogP (<5) Hydrogen Bond Acceptor
Hydrogen Bond 
Donorcode
V2 597.724 4.949 11 3 V29 513.646 4.573 8 2
V3 487.608 4.041 8 2 V30 501.635 4.428 8 2
V12 556.498 5.348 8 2 V31 487.608 4.041 8 2
V13 486.62 4.646 7 2 V32 501.635 4.429 8 2
V14 501.635 4.349 8 2 V33 487.608 4.039 8 2
V15 515.662 4.603 8 2 V34 472.593 4.708 7 2
V16 529.689 4.993 8 2 V35 458.566 4.889 7 2
V17 375.432 3.899 6 2 V36 460.538 3.736 8 2
V18 409.877 4.552 6 2 V37 503.607 3.643 9 3
V19 405.458 3.908 7 2 V38 448.527 3.957 8 3
V20 409.877 4.552 6 2 V39 449.511 3.924 8 2
V21 405.458 3.908 7 2 V40 405.458 3.908 7 2
V22 487.608 4.041 8 2 V41 449.511 3.924 8 2
V23 473.581 3.651 8 2 V42 487.608 4.041 8 2
V24 501.635 4.429 8 2 V43 479.537 3.933 9 2
V25 513.646 4.573 8 2 V44 517.634 4.049 9 2
V26 517.634 3.667 9 2 V46 522.053 4.694 8 2
V27 613.744 4.718 9 2 V50 486.62 4.646 7 2
V28 487.608 4.087 8 3      
Regarding acute oral toxicity, based on the ProTox 
results, V37 compound was of moderate toxicity (Hodge and 
Sterner, 2005), with a LD50 value of 300 mg/kgBB and in class 
III Global Harmoni System (GHS) indicating that it could be 
toxic if swallowed (Drwal et al., 2014). Compound V34 had an 
LD50 value of 3,550 mg/kgBW and in class V GHS, so harmful 
if swallowed (Drwal et al., 2014). It belongs to class IV (500–
5.000 mg/kgBB) according to Hodge and Sterner (2005), so it is 
mildly toxic. The thirty-three other compounds had LD50 values 
between 380–1130 mg/kgBW and were class IV GHS IV toxicity 
class, indicating that they are dangerous if swallowed (Drwal et 
al., 2014). Furthermore, they were also class III (50–500 mg/
kgBW) to grade IV (500–5000 mg/kgBW), which means they had 
moderate to mild toxicity (Hodge and Sterner, 2005).
Based on the results of ADMET Predictor, hepatotoxicity 
test, endocrine system toxicity, and repro toxicity, it can be seen 
that compounds V3, V14, V15, V23-V33, V35, V36, and V46 are 
predicted to have no toxic risk to liver function, the endocrine 
system, and the reproduction system. Hepatotoxicity predicts 
five increased serum enzymes for the diagnosis of liver damage, 
namely alkaline phosphatase (ALP), gamma glutamyl transferase 
(GGT), lactate dehydrogenase (LDH), aspartate transaminase/
serum glutamate oxaloacetate transferase (AST/SGOT), and 
alanine transaminase/serum glutamate pyruvate transferase (ALT/
SGPT). Hepatotoxicity prediction is issued by the Food and Drug 
Administration (FDA) on the side effects for human liver, based on 
two databases, the Spontaneous Reporting System (SRS) and the 
Adverse Event Reporting System (AERS). SRS data distinguishes 
three classes of compounds: inactive (RI < 3.0), slightly active 
(3.0 ≤ RI < 4.0), and active (RI ≥ 4.0). The ADMET Predictor sets 
the RI cut-off value at 3.0, therefore, the molecule with an RI < 3.0 
is categorized as negative (normal) and with RI ≥ 3.0 as positive 
(not normal) in each enzyme (Hassan et al., 2013; Simulations 
Plus, 2016).
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Table 3: Toxicity prediction results from Lazar, ProTox, and ADMET predictor.
Comp. Code A B C D E F G H I J K L M N O Total Average
V12 1 2 2 0 1 500 4 2 2 2 2 2 2 2 2 526 35.06
V13 1 2 2 7.57 1 500 4 2 2 1 2 2 1 2 2 531 35.43
V14 2 2 2 0 1 1000 4 2 2 2 2 2 2 2 2 1027 68.46
V15 2 2 2 0 1 1000 4 2 2 2 2 2 2 2 2 1027 68.46
V16 1 2 2 0 1 1000 4 2 2 2 2 2 2 1 2 1025 68.33
V17 1 1 2 0 1 1060 4 2 1 1 2 2 2 2 2 1083 72.20
V18 2 2 2 0 1 1000 4 2 1 1 2 2 2 2 2 1025 68.33
V19 1 1 2 0 1 1130 4 2 1 1 2 2 2 2 2 1153 76.87
V20 1 1 2 0 1 1130 4 2 1 1 2 2 2 2 2 1153 76.86
V21 2 2 2 0 1 1000 4 2 1 1 2 2 2 2 2 1025 68.33
V22 1 1 2 0 1 625 4 2 2 1 2 2 2 2 2 649 43.26
V23 1 1 2 0 1 500 4 2 2 2 2 2 2 2 2 525 35.00
V24 1 1 2 0 1 500 4 2 2 2 2 2 2 2 2 525 35.00
V25 2 2 2 0 1 500 4 2 2 2 2 2 2 2 2 527 35.13
V26 2 2 2 0 1 380 4 2 2 2 2 2 2 2 2 407 27.13
V27 1 1 2 0 1 1000 4 2 2 2 2 2 2 2 2 1025 68.33
V28 1 1 2 0 1 500 4 2 2 2 2 2 2 2 2 525 35.00
V29 2 2 2 0 1 1000 4 2 2 2 2 2 2 2 2 1027 68.46
V30 1 1 1 0 1 500 4 2 2 2 2 2 2 2 2 524 34.93
V31 2 2 2 0 1 500 4 2 2 2 2 2 2 2 2 527 35.13
V32 1 1 1 0 1 1000 4 2 2 2 2 2 2 2 2 1024 68.26
V33 1 1 2 0 1 500 4 2 2 2 2 2 2 2 2 525 35.00
V34 2 2 2 0 1 3550 5 2 2 1 2 2 2 2 2 3577 238.46
V35 1 1 1 0 1 1000 4 2 2 2 2 2 2 2 2 1024 68.26
V36 1 1 1 0 1 500 4 2 2 2 2 2 2 2 2 524 34.933
V37 1 2 2 0 1 300 3 2 2 1 2 2 2 2 2 324 21.60
V38 1 1 2 0 1 500 4 2 2 1 2 2 2 2 2 524 34.93
V39 2 2 2 0 1 1060 4 2 2 1 2 2 2 2 2 1086 72.40
V40 2 2 2 0 1 1130 4 2 1 1 2 2 2 2 2 1155 77.00
V41 2 2 2 0 1 1060 4 2 2 1 2 2 2 2 2 1086 72.40
V42 2 2 2 0 1 500 4 2 2 1 2 2 2 2 2 526 35.06
V43 2 2 2 0 1 1060 4 2 2 1 2 2 2 2 2 1086 72.40
V44 1 1 2 0 1 500 4 2 2 1 2 2 2 2 2 524 34.93
V46 2 2 2 0 1 500 4 2 2 2 2 2 2 2 2 527 35.13
V50 1 1 2 0 1 740 4 2 2 1 2 2 2 2 2 764 50.93
where A: Hamster Carcinogenicity Test, B: House mouse Carcinogenicity Test , C: Mouse Carcinogenicity Test, D: Maximal Daily Dosage, E: Mutagenicity Test, F: 
LD50, G: Toxicity Class (Class 1-6), H: ALP Test, I: GGT Test, J: LDH Test, K: AST Test, L: ALT Test, M: Oestrogen Test, N: Androgen Test, O: Reprocytocity Test, 
0: unknown, 1: Positive Toxicity, 2: Negative Toxicity.
Based on the results of the scoring calculations of the 
three software applications in Table 3, the compound with the 
lowest toxicity has the highest average scores, which is V34, 
predicted to cause toxicity to LDH enzymes and V19, V20, and 
V40 predicted to be toxic to GGT and LDH enzymes. V43 is 
less effective than the best compound due to its high LD50 value 
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and predicted to be toxic to the liver. Therefore, further analysis 
is required by comparing the number of non-toxic endpoints for 
each compound.
From the analysis results, it is predicted that V14, V15, 
V25, V26, V29, V31 and V46 compounds have no carcinogenic, 
toxic effects on the liver, endocrine systems, and reproductive 
systems, but they are predicted to have mutagenic effects. The 
higher the LD50 of a compound, the lower the toxic effect. V14, 
V15, and V29 compounds have an LD50 of 1.000 mg/kgBW, V25, 
V31, and V46 have an LD50 of 500 mg/kgBW, while V26 has an 
LD50 of 380 mg/kgBW, so V26 compound was not selected for the 
lowest toxic effect.
The lowest mutagen effect has the smallest mutagenic 
probability value. V14, V15, V25, V29, V31 and V46 compounds 
have mutagenic probability values of 0.129, 0.125, 0.107, 0.0988, 
0.159 and 0.127 respectively, so V31 was not selected for the 
lowest toxic effect. V14, V15, V25, V29, and V32 have the lowest 
toxicity with IC50 values of 0.6 nM, 0.5 nM, 0.6 nM, 0.2 nM and 
0.3 nM respectively.
CONCLUSION
The in silico applications, Lazar, ProTox, and 
ADMET, were used to predict the toxicity of anticancer 
pyrazolylaminoquinazolin compounds, revealing that the two 
compounds with the highest activity and the lowest toxicity 
were V29 (N-(5-(3,5-dimethoxy phenethyl)-1H-pyrazol-3-yl)-
7(octahydro-2H-pyrido [1,2-a] pyrazine-2-yl) quinazoline-4-
amine), with a IC50 of 0.2 ± 0.1 nM and a toxicity score of 1027, 
and V32 (N-(5-(3,5-dimethoxy phenethyl)-1H-pyrazol-3-yl)-7-
(4-(dimethylamino)piperidine-1-yl)quinazoline-4-amine) with an 
IC50 of 0.3 ± 0.1 nM and a toxicity score of 1024.
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